Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • AI and healthcare
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
      • Top Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • AI and healthcare
    • Industry Perspective
  • Home
  • MD Brand Connect
  • US FDA clears Roche's...

US FDA clears Roche's Elecsys® pTau217 blood test, developed in collaboration with Lilly, to aid identification of amyloid pathology associated with Alzheimer's disease

Written By : Medical Dialogues Team Published On 2026-09-16T12:10:34+05:30  |  Updated On 17 Sept 2026 10:50 AM IST
US FDA clears Roches Elecsys® pTau217 blood test, developed in collaboration with Lilly, to aid identification of amyloid pathology associated with Alzheimers disease
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

The US Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test¹, developed by Roche in collaboration with Eli Lilly and Company, to aid in identifying amyloid pathology associated with Alzheimer's disease.

The test provides clinicians across primary and specialty care with a single blood-based option to aid in identifying amyloid pathology in individuals aged 55 years and older with signs, symptoms, or complaints of cognitive decline. Elecsys® pTau217 is the first and only FDA-cleared, single-biomarker blood test that supports both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings.

The clearance comes amid increasing interest in blood-based biomarkers as tools that could make assessment of Alzheimer’s disease pathology more accessible and less invasive.

Traditional approaches used to assess amyloid pathology, including positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, may be costly, invasive, and difficult to access outside specialty centres.

Blood Test May Help Address Barriers to Alzheimer’s Disease Assessment

The Elecsys® pTau217 blood test helps address these barriers by providing a minimally invasive blood-based option that can be incorporated into existing clinical and laboratory workflows. The test may help clinicians assess the likelihood of amyloid pathology earlier in the disease and diagnostic pathway and identify patients who should be considered for additional evaluation or specialist referral.

The assay provides positive, intermediate, and negative result categories to support assessment of the likelihood of amyloid pathology. Results are interpreted in conjunction with clinical information and other relevant findings as part of the Alzheimer’s disease diagnostic pathway.

In India, an estimated 7.4% of people aged 60 years and older live with dementia, representing approximately 8.8 million individuals. If this prevalence remains the same, the number of people living with dementia is projected to reach 16.9 million by 2036, driven by the growth of the older Indian population².

Elecsys® pTau217 may help healthcare providers and health systems support clinical decision-making across primary and specialty care, identify appropriate next steps based on the likelihood of amyloid pathology, and facilitate a more efficient diagnostic pathway by offering a minimally invasive blood-based option to help determine when targeted further evaluation, including PET imaging or CSF testing, may be appropriate.

The test’s rule-in and rule-out capabilities using the same clinical cutoffs could also support assessment at different stages of the diagnostic pathway.

Despite the FDA clearance, Elecsys® pTau217 is not intended to be used as a standalone diagnostic test for Alzheimer’s disease. Test results should be interpreted along with clinical information and other relevant diagnostic findings. A result indicating the likelihood of amyloid pathology does not, by itself, establish a diagnosis of Alzheimer’s disease.

The FDA clearance adds to the growing clinical use of blood-based biomarkers in Alzheimer’s disease assessment. For clinicians evaluating older adults presenting with cognitive decline, the availability of a blood-based test that can support both rule-in and rule-out assessment of amyloid pathology could provide an additional practical tool within the evaluation and diagnostic pathway.

References:

1) Roche. Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care [Internet]. Basel (Switzerland): Roche; 2026 Aug 24 [cited 2026 Aug 26]. Available from: https://www.roche.com/investors/updates/inv-update-2026-08-24

2) Lee J, et. al Prevalence of dementia in India: National and state estimates from a nationwide study. Alzheimers Dement. 2023 Jul;19(7):2898-2912. doi: 10.1002/alz.12928. Epub 2023 Jan 13. Erratum in: Alzheimers Dement. 2025 Jul;21(7):e70555. doi: 10.1002/alz.70555. PMID: 36637034; PMCID: PMC10338640.

CMAT-22226 | 27/08/2026

The information provided in this section is intended solely for the use of registered medical practitioner. For further Information about Lilly and Lilly products please contact us at: Atrium Place, 11th Floor, Tower B, Block C, Vanijya Nikunj, Phase V, Udyog Vihar, Sector 19, Gurugram, Haryana 122016. Ph.: +91-124-4753000/01 | www.lilly.com/in. For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com. For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com . This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. This material is being provided to healthcare professionals only for their guidance and use. Nothing on this material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.

© 2026 Eli Lilly and Company. All Rights Reserved

Eli Lilly Privacy Policy: https://privacynotice.lilly.com/global/

RocheElecsys pTau217pTau217 blood testAlzheimer's diseaseamyloid pathologyblood-based biomarkercognitive declinePET imagingCSF testingLillydementiaalzheimerUS FDAUSFDA Approval

Medical Survey

Medical Dialogues Team
Medical Dialogues Team
    Print Article
    Show Full Article
    Next Story
    Recommended For You
    NO DATA FOUND

    Editorial

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Dapagliflozin Metformin in T2D: Five Evidence Insights Relevant for Clinicians

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev Joshi

    Jural Exploitation of Healthcare Professionals and Institutions in the PM-RAHAT Scheme - Dr Rajeev...

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Metformin - Eight Points on a Metabolic Anchor in T2D: World Diabetes Day Special

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination - Dr. Makarand Damle

    Clinical Insights for Allergic Rhinitis Management with Fexofenadine and Pseudoephedrine Combination...

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    Effect of Saroglitazar in MASLD: Latest Indian 2026 Study

    View All

    Journal Club Today

    Muscle Loss or Water Loss? Researchers Examine Effects of Ketogenic Diets on Body Composition

    Muscle Loss or Water Loss? Researchers Examine Effects of Ketogenic Diets on Body Composition

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok